Premium
Design, Synthesis, and Antitumor Activity of ( E,Z )‐1‐(dihydrobenzofuran‐5‐yl)‐3‐phenyl‐2‐(1,2,4‐triazol‐1‐yl)‐2‐propen‐1‐ones
Author(s) -
Li Wan,
Yang ZiHui,
Hu AiXi,
Yan XiaoWei,
Ding Na,
Ye Jiao
Publication year - 2015
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12601
Subject(s) - hela , cytotoxicity , stereochemistry , chemistry , apoptosis , in vitro , a549 cell , ic50 , cell cycle , structure–activity relationship , cell cycle checkpoint , biochemistry
A series of ( E,Z )‐1‐(dihydrobenzofuran‐5‐yl)‐3‐phenyl‐2‐(1,2,4‐triazol‐1‐yl)‐2‐propen‐1‐ones ( C1 – C35 ) were designed and synthesized, and the structures of compounds ( Z )‐ C27 and ( Z )‐ C29 were confirmed by single‐crystal X‐ray diffraction. The antitumor activities of these novel compounds against cervical cancer (HeLa), lung cancer (A549), and breast cancer ( MCF ‐7) cell lines were evaluated in vitro . Majority of the title compounds exhibited strong antitumor activities and were much more promising than the positive control Taxol, which were also accompanied by lower cytotoxicity to normal cells. In particular, compounds ( E,Z )‐ C24 exhibited the most consistent potent activities against three neoplastic cells with IC 50 values ranging from 3.2 to 7.1 μ m . Further researches demonstrated that compounds ( E,Z )‐ C24 could induce cell apoptosis and arrest cell cycle at the G2/M and S phases. Meanwhile, the structure–activity relationship between the configurations and cytotoxicity of the compounds was also investigated.